Researchers uncover key mechanisms driving oral cancer spread and highlight potential treatment strategies
A collaborative research team from The University of Hong Kong (HKU) and West China Hospital of Sichuan University has made a breakthrough in understanding the spread of oral squamous cell carcinoma ...
CNBCTV182d
Shilpa Medicare arm partners with Switzerland-based mAbTree Biologics for new cancer drug
While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a ...
MedPage Today on MSN3d
No Benefit With CRT Versus RT in Cervical Cancer After Radical Hysterectomy
The addition of concurrent cisplatin chemotherapy to adjuvant radiation therapy (CRT), versus RT alone, couldn't move the ...
Targeted Oncology5d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Targeted Oncology6d
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.
'Scaly patch' that's not a mole could be a sign of cancer
There are two main types of skin cancer; Non-melanoma skin cancer and melanoma. Non-melanoma skin cancer, which slowly ...